Document:

Binding Letter of Intent and Termination Agreement, dated August 23, 2004

 Exhibit 10.2 
  
 Hopkins Capital Group II, LLC 
 709 The Hamptons Lane 
 St. Louis, MO 63017 
  
 BINDING LETTER OF INTENT AND TERMINATION AGREEMENT 
  
 August 23, 2004 
  
 BioDelivery Sciences International, Inc. 
 UMDNJ-New Jersey Medical School 
 185 South Orange Avenue, Administrative Building 4 
 Newark, NJ 07103 
  
 Ladies and Gentlemen:

  
 Reference is made to that certain Facility Loan Agreement,
dated August 2, 2004 (the “Loan Agreement”), by and between BioDelivery Sciences International, Inc. (“BDSI”) and Hopkins Capital Group II, LLC (“HCG”). Subject to formal approval of BDSI’s
Board of Directors and completion of legal documentation satisfactory to all parties, we are pleased to provide you with this letter agreement (this “Agreement”) to set forth the agreement of BDSI and HCG with respect to: (i) the
termination of the Loan Agreement and (ii) the entry into by the parties of an Equity Line of Credit Agreement (the “Equity Line Agreement”) to replace the Loan Agreement upon the terms set forth herein. 
  
 By executing this Agreement, the parties confirm their intentions specified
herein with respect to the Equity Line Agreement. This Agreement is intended by the parties to be, and is and shall be, legally binding and enforceable upon the execution of this Agreement unless and until modified or terminated by the final Equity
Line Agreement. For the avoidance of doubt, should the Equity Line Agreement not be entered into, the terms of this Agreement shall nonetheless remain enforceable and binding on the parties. 
  
 1. Termination of Loan Agreement. Pursuant to the terms of the Loan
Agreement, BDSI and HCG hereby unconditionally terminate the Loan Agreement, agree that no party thereto shall hereinafter have any rights or obligations thereunder and release each other and their respective affiliates from any and all claims of
action that the parties may have against one another thereunder. Any and all amounts funded as of or prior to the date hereof under the Loan Agreement shall be deemed for all purposes to have been contributed to BDSI in consideration for shares of
BDSI Series B Preferred (as defined below) and otherwise on the terms set forth herein and in the Equity Line Agreement. 
  
 2. Equity Line Agreement. Pursuant to the Equity Line Agreement, HCG agrees, at the request of BDSI, to invest up to $4,000,000 in BDSI from August
23, 2004 through March 31, 2006 in consideration of shares of a newly created class of Series B Convertible Series B Preferred of BDSI (the “Series B Preferred”). The terms of the Series B Preferred shall be as follows: 

 

			
	 Rights, Preferences
 Privileges and Restrictions:
	 	Designation and Amount; Rank: The Series B Preferred shall be a newly designated series of shares of preferred stock of BDSI. The Series B Preferred shall rank senior to the shares of
common stock, par value $0.01 per share, of BDSI (the “BDSI Common Stock”) and the shares of BDSI’s Series A Non-Voting Convertible Preferred Stock

			
	 	 	(collectively, with the BDSI Common Stock and all shares of capital stock of BDSI which are junior to the Series B Preferred, the “Junior Stock”).
		
	 	 	Dividends: The holders of the Series B Preferred shall be entitled to receive a 4.5% annual cumulative dividend in preference to the holders of Junior Stock.
		
	 	 	 Liquidation Preference: In the event of any liquidation or winding up of the Company, the holders of the Series B Preferred shall be entitled
to receive, pro rata and in preference to the holders of Junior Stock, an amount (the “Preferential Amount”) equal to the sum of:
  
 (a) all amounts funded to BDSI under the Equity Line Agreement; plus
  
 (b) all accrued but unpaid dividends on the shares of Series B Preferred issued in consideration of such
fundings.
  
 A merger or other corporate reorganization in which the
Company’s stockholders shall receive cash or securities of another corporation, or any transaction in which all or substantially all of the assets of the Company are sold shall be treated as a liquidation for purposes of the liquidation
preference. Holders of Series B Preferred shall receive prior notice of any such transaction and an opportunity to convert their Series B Preferred prior to the consummation of such transaction.
  
 After payment of the Preferential Amount, the remaining assets or property distributable upon
such liquidation shall be divided pro rata among the holders of Junior Stock and not holders of Series B Preferred.

		
	 	 	Redemption: BDSI may, at any time, and in its discretion, elect to redeem the shares of Series B Preferred at a cash price equal to the face value of the amount invested plus accrued
dividends through the date of redemption. The holders of Series B Preferred shall not have the right to cause the Company to redeem or repurchase such shares at any time.
		
	 	 	 Conversion: Each holder of the Series B Preferred shall have the immediate right to convert such holder’s shares of Series B Preferred
into shares of BDSI Common Stock as follows:
  
 (a) at any
time as of or after April 1, 2006 at a price equal to $4.25 (the “Series B Preferred Purchase Price”); or
  
 (b) upon a Change of Control (as that term is presently defined in the Loan Agreement).

		
	 	 	Voting Rights: The holders of Series B Preferred will have not voting rights until conversion into BDSI Common Stock, provided that BDSI will not amended the Certificate of Designations
of the Series B Preferred without the consent of HCG.

  

 2 

			
	 	  	Protective Provisions: The Series B Preferred will carry the identical affirmative and negative covenants as were provided for under the Loan Agreement.
		
	Antidilution Provisions:	  	The Series B Preferred Purchase Price will be subject to proportional antidilution protection for Splits.
		
	Registration Rights:	  	The holders of the Series B Preferred will carry the identical registration rights for the shares of BDSI Common Stock receivable upon conversion of the Series B Preferred were provided for
under the Loan Agreement.
		
	Documentation:	  	The parties shall prepare appropriate documentation to memorialize the Equity Line Agreement and the Series B Preferred as soon as is commercially practicable following the date hereof but in
no event later than September 3, 2004.

  
 3. Governing
Law. This Agreement and the Equity Line Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey applicable to agreements made and to be fully performed therein, without regard to conflicts of law
principles. 
  
 4. Amendments. This Agreement may not be
modified or amended except in a writing duly executed by the parties hereto. 
  
 5. Headings. The section headings in this Agreement have been inserted as a matter of reference and are not part of this Agreement. 
  
 6. Successors and Assigns. The benefits of this Agreement shall inure to the parties hereto, their respective
successors and assigns and to the indemnified parties hereunder and their respective successors and assigns, and the obligations and liabilities assumed in this Agreement shall be binding upon the parties hereto and their respective successors and
assigns. Notwithstanding anything contained herein to the contrary, neither party shall assign any of its obligations hereunder without the prior written consent of the other party. 
  
 7. No Third Party Beneficiaries. This Agreement does not create, and shall not be construed as creating, any rights
enforceable by any person or entity not a party hereto. 
  
 8.
Waiver. Any waiver or any breach of any of the terms or conditions of this Agreement shall not operate as a waiver of any other breach of such terms or conditions or of any other term or condition, nor shall any failure to insist upon strict
performance or to enforce any provision hereof on any one occasion operate as a waiver of such provision or of any other provision hereof or a waiver of the right to insist upon strict performance or to enforce such provision or any other provision
on any subsequent occasion. Any waiver must be in writing. 
  
 9.
Counterparts. This Agreement may be executed in any number of counterparts and by facsimile transmission, each of which shall be deemed to be an original instrument, but all of which taken together shall constitute one and the same agreement.
Facsimile signatures shall be deemed to be original signatures for all purposes. 
  

 3 

 If the foregoing correctly sets forth our agreement, please sign the enclosed copy of this Agreement in
the space provided below and return it to us. 
  

			
	 Very truly yours,

	
	 HOPKINS CAPITAL GROUP II, LLC

		
	 By:
	 	 /s/ Francis E. O’Donnell, Jr.

	 Name:
	 	 Francis E. O’Donnell, Jr.

	 Title:
	 	 Manager

  
 Agreed to and accepted this
23rd day of August, 2004 
  
 BioDelivery Sciences International, Inc.

  

			
	 By:
	 	 /s/ James A. McNulty

	 Name:
	 	 James A. McNulty

	 Title:
	 	 Secretary, Treasurer and Chief Financial Officer

  
 [Signature Page to
Binding Letter Agreement] 
  

 4Registration Rights Agreement, dated August 24, 2004

 Exhibit 10.3 
  
 REGISTRATION RIGHTS AGREEMENT 
  

This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into effective as of August 24, 2004, by and between
BioDelivery Sciences International, Inc., a Delaware corporation (the “Company”) and the other persons and entities signatory hereto (collectively, the “Series A Stockholders”). 
  
 RECITALS 
  
 WHEREAS, pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of August 10, 2004, the
Company has agreed to grant to the Series A Stockholders the registration rights set forth herein. 
  
 NOW, THEREFORE, to implement the foregoing and in consideration of the mutual terms, conditions and covenants contained herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows: 
  

1. Piggyback Registration. 
  
 (a) Right to Piggyback Registration. Subject to the terms hereof, whenever the Company proposes to register any Company Equity Securities under the
Securities Act (other than pursuant to a registration statement on Form S-4, Form S-8 or any successor form) and the registration statement form to be used may be used for the registration of Registrable Securities, the Company shall give prompt
written notice to the Series A Stockholders of its intention to effect such a registration. Subject to Section 1(b) below, the Company shall include in such registration and use commercially reasonable efforts to include in any underwriting all
shares of Registrable Securities held by the Series A Stockholders with respect to which the Company has received a written request from the Series A Stockholders for inclusion therein within 30 days after the receipt of the Company’s notice
(such registration, a “Piggyback Registration”). 
  
 (b) Priority on Primary Registrations. If a Piggyback Registration is an underwritten primary registration on behalf of the Company, and the managing underwriters advise the Company in writing that in their opinion the number of
securities requested to be included in such registration exceeds the number which can be sold without materially and adversely affecting the marketability of such offering or the timing thereof, the Company shall include in such registration all
Registrable Securities held by the Series A Stockholders on the condition that the Series A Stockholders will agree to refrain from selling a reasonable number of such Registrable Securities (as determined in good faith by the Company based on the
impact on the timing and marketability of the offering of the sale immediate by the Series A Stockholders of all of its Registrable Securities) for a three (3) month period following the declaration of effectiveness of the applicable registration
statement. 
  
 2. Registration Procedures. Whenever the Series A
Stockholders request that any Registrable Securities be registered pursuant to this Agreement, the Company shall use its 

 commercially reasonable efforts to effect the registration and the sale of such Registrable Securities in accordance with
the intended method of disposition thereof, and pursuant thereto the Company shall as expeditiously as possible: 
  
 (a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its reasonable best efforts to cause such
registration statement to become effective; 
  
 (b) notify the
Series A Stockholders of the effectiveness of each registration statement filed hereunder and prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be
necessary to keep such registration statement effective and the prospectus included therein usable for a period commencing on the date that such registration statement is initially declared effective by the SEC and ending on the date when all
Registrable Securities covered by such registration statement have been sold pursuant to the registration statement or cease to be Registrable Securities, and comply with the provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement during such period in accordance with the intended methods of disposition by the sellers thereof set forth in such registration statement; 
  
 (c) furnish to the Series A Stockholders such number of copies of such
registration statement, each amendment and supplement thereto, the prospectus included in such registration statement (including each preliminary prospectus) and such other documents as such seller may reasonably request in order to facilitate the
disposition of the Registrable Securities owned by the Series A Stockholders; 
  
 (d) use its commercially reasonable efforts to register or qualify such Registrable Securities under such other securities or blue sky laws of such jurisdictions as the Series A Stockholders reasonably requests and do
any and all other acts and things which may be reasonably necessary or advisable to enable the Series A Stockholders to consummate the disposition in such jurisdictions of the Registrable Securities owned by the Series A Stockholders; provided, that
the Company shall not be required to: (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this subparagraph; (ii) subject itself to taxation in any such jurisdiction; or (iii) consent
to general service of process in any such jurisdiction; 
  
 (e)
notify the Series A Stockholders, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event as a result of which the prospectus included in such registration statement contains
an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading, and, at the request of the Series A Stockholders, the Company shall prepare a supplement or amendment to such prospectus so that, as
thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading; 
  
 (f) cause all such Registrable Securities to be listed or quoted on each
securities exchange or market on which similar securities issued by the Company are then listed; 
  

 2 

 (g) provide a transfer agent and registrar for all such Registrable Securities not later than the
effective date of such registration statement; 
  
 (h) enter into
such customary agreements (including underwriting agreements in customary form) in order to expedite or facilitate the disposition of such Registrable Securities; 
  
 (i) make available for inspection by any underwriter participating in any disposition pursuant to such registration
statement, and any attorney, accountant or other agent retained by any such underwriter, all financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers, directors, managers,
employees and independent accountants to supply all information reasonably requested by any such underwriter, attorney, accountant or agent in connection with such registration statement; 
  
 (j) otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations of the SEC, and
make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least 12 months beginning with the first day of the Company’s first full calendar quarter after the effective date of the
registration statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder; 
  
 (k) in the event of the issuance of any stop order suspending the effectiveness of a registration statement, or of any order suspending or preventing the
use of any related prospectus or suspending the qualification of any Registrable Securities included in such registration statement for sale in any jurisdiction, the Company shall use its reasonable best efforts promptly to obtain the withdrawal of
such order; 
  
 (l) subject to Section 2(d) above, use its
reasonable best efforts to cause any Registrable Securities covered by such registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the sellers thereof to consummate
the disposition of such Registrable Securities; and 
  
 (m) if the
offering is underwritten, use its reasonable best efforts to furnish on the date that Registrable Securities are delivered to the underwriters for sale pursuant to such registration, an opinion dated such date of counsel representing the Company for
the purposes of such registration, addressed to the underwriters covering such issues as are reasonably required by such underwriters. 
  
 3. Registration Expenses. 
  
 (a) Payment of Registration Expenses. All expenses incident to the Company’s performance of or compliance with this Agreement, including
without limitation all registration and filing fees, fees and expenses of compliance with securities or blue sky laws, printing expenses, messenger and delivery expenses, fees and disbursements of custodians, and fees and disbursements of counsel
for the Company and all independent certified public accountants, underwriters (excluding underwriting discounts and commissions relating to the Registrable Securities) and other Persons retained by the Company (all such expenses being herein called
“Registration Expenses”), shall be borne by the Company. The Company shall, in addition, pay 
  

 3 

 its internal expenses (including, without limitation, all salaries and expenses of its officers and employees performing
legal or accounting duties), the expense of any annual audit or quarterly review, the expense of any liability insurance and the expenses and fees for listing or quoting the securities to be registered on each securities exchange on which similar
securities issued by the Company are then listed or on the NASDAQ Stock Market. 
  
 (b) Payment of Registration Expenses by Holders of Registrable Securities. To the extent Registration Expenses are not required to be paid by the Company (including, without limitation, any underwriting
discounts or commissions that are the responsibility of the holders of Registrable Securities), each holder of the Series A Stockholders shall pay those Registration Expenses allocable to the registration of the Series A Stockholders’
securities so included, and any Registration Expenses not so allocable shall be payable by all sellers of securities included in such registration in proportion to the aggregate selling price of the securities to be so registered. 
  
 4. Indemnification. 
  
 (a) Indemnification by The Company. The Company agrees to indemnify,
to the extent permitted by law, the Series A Stockholders and their agents and representatives against all losses, claims, damages, liabilities and expenses caused by any untrue or alleged untrue statement of material fact contained in any
registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not
misleading, except insofar as the same are caused by or contained in any information furnished in writing to the Company by such holder expressly for use therein, results from the failure of the Series A Stockholders to provide information necessary
for the registration statement to the Company, or by the Series A Stockholders’ failure to deliver a copy of the registration statement or prospectus or any amendments or supplements thereto after the Company has furnished such holder with a
sufficient number of copies of the same. 
  
 (b)
Indemnification by the Series A Stockholders. In connection with any registration statement in which the Series A Stockholders is participating, the Series A Stockholders shall furnish to the Company in writing such information and affidavits
as the Company reasonably requests for use in connection with any such registration statement or prospectus and, to the extent permitted by law, shall indemnify the Company, its officers, directors, employees, agents and representatives and each
Person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses resulting from any untrue or alleged untrue statement of material fact contained in the registration statement,
prospectus or preliminary prospectus or any amendment thereof or supplement thereto resulting from such information provided by the Series A Stockholders or any omission or alleged omission of a material fact required to be stated therein or
necessary to make the statements therein not misleading and not provided by the Series A Stockholders; provided that the obligation to indemnify shall be be limited to the net amount of proceeds received by the Series A Stockholders from the sale of
Registrable Securities pursuant to such registration statement. 
  
 (c) Procedure For Indemnification. Any Person entitled to indemnification hereunder shall: (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification (provided that the
failure to give prompt notice shall not impair any 
  

 4 

 Person’s right to indemnification hereunder to the extent such failure has not prejudiced the indemnifying party)
and (ii) unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim
with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent (but such consent shall not
be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified by such indemnifying
party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim. Notwithstanding
anything in this Section 4(c) to the contrary, in the event the Company determines, in good faith, that a claim materially affects the interests of the Company, the Company may solely control the defense of such claim with counsel reasonably
satisfactory to the Company. In the event the Company is an indemnified party pursuant to this Section 4, the indemnifying party may be subject to liability if the Company settles a claim in good faith and in a reasonable manner. 
  
 5. Participation in Underwritten Registrations. The Series A Stockholders may not
participate in any registration hereunder unless the Series A Stockholders: 
  
 (a) in the case of a registration which is underwritten, agrees to sell the Series A Stockholders’s securities on the basis provided in any underwriting arrangements approved by the Company; 
  
 (b) as expeditiously as possible, notifies the Company, at any time when a
prospectus relating to such the Series A Stockholders’ Registrable Securities is required to be delivered under the Securities Act, of the happening of any event as a result of which such prospectus contains an untrue statement of a material
fact or omits any fact necessary to make the statements therein not misleading; and 
  
 (c) completes, executes and delivers all questionnaires, powers of attorney, indemnities, underwriting agreements and other usual and customary documents necessary or appropriate with respect to the offering of such
the Series A Stockholders’ Registrable Securities, and in the case of a registration which is underwritten, necessary or appropriate under the terms of such underwriting arrangements (subject to the provision in Section 5(a) above). 

 
 6. Definitions. 
  
 (a) The term “Capital Stock” means and includes (a) any and
all shares, interests, participations or other equivalents of or interests in (however designated) corporate stock, including shares of preferred or preference stock and (b) all equity or ownership interests in any Person of any other type,
including any securities convertible into or exchangeable for any of the foregoing or any options, warrants or other rights to subscribe for, purchase or acquire any of the forgoing. 
  

 5 

 (b) The term “Common Stock” means the shares of common stock, par value $.001 per share,
of the Company. 
  
 (c) The term “Company Equity
Securities” means any Capital Stock of the Company or options, warrants or other rights acquire Capital Stock of the Company. 
  
 (d) The term “Person” means any individual, Company, partnership, joint venture, association, joint-stock company, limited liability
company, trust or unincorporated organization. 
  
 (e) The term
“Registrable Securities” means all shares of Common Stock held by the Series A Stockholders or the shares of Common Stock issuable upon the conversion of shares of Series A Stock held by the Series A Stockholders; provided,
however, that as to any particular Registrable Securities that have been issued, such securities shall cease to be Registrable Securities when: (i) a registration statement with respect to the sale of such securities shall have become effective
under the Securities Act and such securities shall have been disposed of under such registration statement, (ii) all Registrable Securities owned by a holder thereof may be resold in a single 90-day period pursuant to Rule 144 under the Securities
Act (or any similar rule then in force), (iii) they shall have been distributed to the public pursuant to Rule 144 under the Securities Act (or any similar rule then in force), (iv) they become available for sale under Rule 144(k) under the
Securities Act (or any similar rule then in force), or (v) they shall have ceased to be outstanding. 
  
 (f) The term “SEC” mean the United Stated Securities and Exchange Commission. 
  
 (g) The term “Securities Act” means the Securities Act of
1933, as amended, or any similar federal law then in force. 
  
 (h) The term “Securities Exchange Act” means the Securities Exchange Act of 1934, as amended, or any similar federal law then in force. 
  
 (i) The term “Series A Stock” means the shares of Series A Non-Voting Convertible Preferred Stock of the
Company, par value $.001 per share. 
  
 7.
Miscellaneous. 
  
 (a) No Inconsistent Agreements.
The Company shall not hereafter enter into any agreement with respect to its securities which is inconsistent with or violates the rights granted to the Series A Stockholders under this Agreement, and in the event that any such agreement is entered
into by the Company, the terms and provisions of this Agreement will prevail over those contained in any such agreement. 
  
 (b) Remedies. Any Person having rights under any provision of this Agreement shall be entitled to enforce such rights specifically to recover
damages caused by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. The parties hereto agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of
this Agreement and that any party may in its sole discretion apply to any court of law or equity of competent jurisdiction (without posting any bond or other security) for specific performance and for other injunctive relief in order to enforce or
prevent violation of the provisions of this Agreement. 
  

 6 

 (c) Amendments And Waivers. Except as otherwise provided herein, the provisions of this Agreement
may be amended or waived only upon the prior written consent of the Company and the Series A Stockholders. 
  
 (d) Successors And Assigns. All covenants and agreements in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the
benefit of the respective successors and assigns of the parties hereto whether so expressed or not. In addition, whether or not any express assignment has been made, the provisions of this Agreement which are for the benefit of purchasers or holders
of Registrable Securities are also for the benefit of, and enforceable by, any subsequent holder of Registrable Securities. Upon any transfer of Registrable Securities, the holder of the Registrable Securities shall use its best efforts to have the
new holder of Registrable Securities sign a joinder agreement pursuant to which such transferee shall agree to be bound by the terms of this Agreement applicable to the holder of such Registrable Securities, provided that, even in the absence of
such joinder agreement, by taking and holding such Registrable Securities, such new holder shall be conclusively deemed to have agreed to be bound by the terms hereof applicable to such new holder. 
  
 (e) Severability. Whenever possible, each provision of this Agreement
shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this Agreement. 
  
 (f) Counterparts; Facsimile Transmission. This Agreement may be executed in two or more counterparts, any one of which need not contain the signatures of more than one party, but all such counterparts taken
together shall constitute one and the same Agreement. Any such counterpart delivered to the Company shall be effective if received by the Company no later than September 6, 2004. Each party to this Agreement agrees that it will be bound by its own
facsimile signature and that it accepts the facsimile signature of each other party to this Agreement. 
  
 (g) Descriptive Headings. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this
Agreement. 
  
 (h) Governing Law. This Agreement shall be
construed and governed in accordance with the laws of the State of New Jersey, without regard to its conflicts of laws principles. 
  
 (i) Notices. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be
in writing and shall be deemed to have been given when delivered in conformance with the applicable provisions of the Merger Agreement. 
  

 7 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	BIODELIVERY SCIENCES INTERNATIONAL, INC.
		
	By:	 	 /s/ Francis E. O’Donnell, Jr.

	Name:	 	Francis E. O’Donnell, Jr.
	Title:	 	President and Chief Executive Officer
	
	SERIES A STOCKHOLDERS:
	
	 /s/ Mark A. Sirgo

	Mark A. Sirgo
	
	 /s/ Andrew L. Finn

	Andrew L. Finn
	
	WYRP FOUNDER’S FUND
		
	By:	 	  

	Name:	 	 
	Title:	 	 
	
	
 Jeff Katz

	
	
 William S. Poole

	
	
 Arthur G. Lipman

	
	
 Delmar A. Nordstrom

  
 [Signature Pages
Continue] 
  

 8 

 Signature Page to Registration Rights Agreement 
  

	
	  

 Celeste
Lindley

	
	
 William McCarberg

	
	
 William Baicy

	
	
 Robert Reuss

  
 [End of Signature
Pages to Registration Rights Agreement] 
  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00071-of-00352.parquet"}]]